0001567619-20-003975.txt : 20200214
0001567619-20-003975.hdr.sgml : 20200214
20200214160623
ACCESSION NUMBER: 0001567619-20-003975
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200212
FILED AS OF DATE: 20200214
DATE AS OF CHANGE: 20200214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Innoviva, Inc.
CENTRAL INDEX KEY: 0001080014
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37544
FILM NUMBER: 20619501
BUSINESS ADDRESS:
STREET 1: 2000 SIERRA POINT PARKWAY
STREET 2: SUITE 500
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 6502389600
MAIL ADDRESS:
STREET 1: 2000 SIERRA POINT PARKWAY
STREET 2: SUITE 500
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER NAME:
FORMER CONFORMED NAME: THERAVANCE INC
DATE OF NAME CHANGE: 20020207
FORMER NAME:
FORMER CONFORMED NAME: ADVANCED MEDICINE INC
DATE OF NAME CHANGE: 20000302
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Armata Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0000921114
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 911549568
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4503 GLENCOE AVENUE
CITY: MARINA DEL REY
STATE: CA
ZIP: 90292
BUSINESS PHONE: 310-665-2928
MAIL ADDRESS:
STREET 1: 4503 GLENCOE AVENUE
CITY: MARINA DEL REY
STATE: CA
ZIP: 90292
FORMER COMPANY:
FORMER CONFORMED NAME: AmpliPhi Biosciences Corp
DATE OF NAME CHANGE: 20130222
FORMER COMPANY:
FORMER CONFORMED NAME: TARGETED GENETICS CORP /WA/
DATE OF NAME CHANGE: 19940331
3
1
doc1.xml
FORM 3
X0206
3
2020-02-12
0
0000921114
Armata Pharmaceuticals, Inc.
ARMP
0001080014
Innoviva, Inc.
1350 OLD BAYSHORE HIGHWAY SUITE 400
BURLINGAME
CA
94010
0
0
1
0
Common Stock
993139
D
Warrants to Purchase Common Stock
2.87
2020-02-12
2025-02-12
Common Stock
993139
D
As reflected in the Schedule 13D filed by Innoviva, Inc. (the "Reporting Person") with the U.S. Securities and Exchange Commission on February 14, 2020 (the "Schedule 13D"), in connection with an initial closing that occurred on February 12, 2020 pursuant to a securities purchase agreement, dated as of January 27, 2020 (the "Purchase Agreement" and, such closing, the "Initial Closing"), by and between Armata Pharmaceuticals, Inc. (the "Issuer") and the Reporting Person, the Reporting Person acquired 993,139 shares of common stock of the Issuer ("Shares") and warrants to purchase an additional 993,139 Shares ("Warrants") as set forth in this Form 3. As a result of the Initial Closing, the Reporting Person beneficially owns 1,983,386 Shares. The Schedule 13D filed by the Reporting Person is incorporated by reference in this Form 3; any description herein of the Schedule 13D is qualified in its entirety by reference to the Schedule 13D so filed by the Reporting Person.
INNOVIVA, INC., By: /s/ Geoffrey Hulme
2020-02-14